(NASDAQ: VRNA) Verona Pharma's forecast annual revenue growth rate of 105% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.9%.
Verona Pharma's revenue in 2025 is $118,535,000.On average, 5 Wall Street analysts forecast VRNA's revenue for 2025 to be $278,517,860,197, with the lowest VRNA revenue forecast at $251,370,967,160, and the highest VRNA revenue forecast at $297,144,742,399. On average, 5 Wall Street analysts forecast VRNA's revenue for 2026 to be $508,074,602,972, with the lowest VRNA revenue forecast at $389,489,128,422, and the highest VRNA revenue forecast at $611,894,782,966.
In 2027, VRNA is forecast to generate $681,412,214,300 in revenue, with the lowest revenue forecast at $519,196,247,811 and the highest revenue forecast at $789,500,572,383.